Clostridium difficile: A healthcare-associated infection of unknown significance in adults in sub-Saharan Africa by Keeley, Alexander J et al.
Malawi Medical Journal 28 (2): June 2016 C. diff in sub-Saharan Africa   66
MMJ VOL 28 (2): June 2016http://dx.doi.org/10.4314/mmj.v28i2.8
Review
Clostridium difficile: A healthcare-associated infection 
of unknown significance in adults in sub-Saharan 
Africa                      
Alexander J. Keeley1, Nicholas J. Beeching1,2,3, Katharine E. Stott1, Paul Roberts4, Alastair J. Watson5, 
Michael B.J. Beadsworth1,2
1. Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom 
2. Department of  Clinical Sciences, Liverpool School of  Tropical Medicine, Liverpool, United Kingdom
3. National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections, University of  Liverpool, Liverpool, United 
Kingdom
4. Department of  Infection and Immunity, Royal Liverpool University Hospital, Liverpool, United Kingdom
5. National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections, Norwich Medical School, University of  East 
Anglia, Norwich Research Park, Norwich, United Kingdom
Correspondence to: Michael B.J. Beadsworth (Mike.Beadsworth@rlbuht.nhs.uk)
Abstract
Background
Clostridium difficile infection (CDI) causes a high burden of  disease in high-resource healthcare systems, with significant morbidity, 
mortality, and financial implications. CDI is a healthcare-associated infection for which the primary risk factor is antibiotic usage, and it is 
the leading cause of  bacterial diarrhoea in HIV-infected patients in the United States. Little is known about the disease burden of  CDI in 
sub-Saharan Africa, where HIV and healthcare-associated infections are more prevalent and antibiotic usage is less restricted. This article 
reviews published literature on CDI in sub-Saharan Africa, highlighting areas for future research. 
Methods
English language publications since 1995 were identified from online databases (PubMed, Medline, Google Scholar, and SCOPUS), using 
combinations of  keywords “C. difficile”, “Africa”, and “HIV”.
Results
Ten relevant studies were identified. There was considerable variation in the methodologies used to assess for carriage of  toxigenic C. 
difficile and its associations. Eight studies reported carriage of  toxigenic C. difficile. Three (of  three) studies found an association with 
antibiotic usage. One (of  four) studies showed an association with HIV infection. One study showed no association with degree of  
immunosuppression in HIV. Two (of  three) studies showed an association between carriage of  toxigenic C. difficile and diarrhoeal illness.
Conclusions
While the carriage of  toxigenic C. difficile is well described in sub-Saharan Africa, the impact of  CDI in the region remains poorly 
understood and warrants further research.
Introduction
Clostridium difficile, an anaerobic gram-positive spore-forming 
bacterium, was first described following isolation from 
neonatal intestinal tissue in 1935, and was initially presumed 
to be a commensal organism.1 C. difficile was later recognised 
to cause pseudomembranous colitis via toxin production, 
and it has since emerged as a major enteric pathogen.2,3 Its 
clinical significance ranges from asymptomatic carriage to 
life-threatening colitis, with significant associated morbidity 
and mortality. C. difficile colonises the large bowel following 
ingestion of  spores, which are heat and acid resistant.4 The 
spores can be found in most healthcare settings and in the 
general environment.5,6 Gut damage in susceptible individuals 
results from production of  the enterotoxin TcdA, which 
damages the intestinal epithelium, and the cytotoxin TcdB, 
which has broader cellular tropism.7 The emergence of  the 
027/BI/NAP1 strain, with dramatically increased cytotoxin 
production, is responsible for the observed increased 
prevalence and virulence of  C. difficile in recent years.8-10 This 
strain emerged in North America and Western Europe and 
rapidly disseminated worldwide.11
The primary risk factor for C. difficile infection (CDI) is 
antibiotic usage. CDI is known to be the cause of  up 
to 25% of  antibiotic-associated diarrhoea.12 CDI was 
originally described following clindamycin use but is now 
known to complicate the use of  many broad-spectrum 
antibiotics, particularly cephalosporins, co-amoxiclav, and 
fluoroquinolones.3,13 Following antibiotic usage, there is an 
imbalance in the normal gut flora and C. difficile overgrowth 
can lead to pseudomembranous colitis in susceptible 
individuals.14 Other described risk factors for CDI include 
hospital admission, exposure to an infected carrier, advanced 
age, and immunosupression.15 The importance of  proton 
pump inhibitors and of  other interventions that reduce 
the gastric acid barrier in increasing susceptibility to CDI 
remains controversial.16,17 There is a described relationship 
between CDI and HIV, wherein C. difficile is known to 
be the leading cause of  bacterial diarrhoea among HIV-
infected populations in the United States, but it is not clear 
how much this reflects increased exposure to healthcare 
compared to HIV-negative individuals.18,19 Only two studies 
show a convincing association between CDI and low CD4 
count, and interpretation of  these results is difficult given 
the high rates of  C. difficile colonisation in HIV-infected 
populations.19-22
While CDI has been extensively researched in well-resourced 
health systems, there are few published studies about CDI in 
sub-Saharan Africa. Healthcare-associated infections cause 
a greater disease burden in healthcare systems with fewer 
resources.23 Furthermore, in sub-Saharan Africa there is 
widespread availability of  broad-spectrum antibiotics and 
fewer controls on their usage.24 Finally, HIV is far more 
prevalent in sub-Saharan Africa than in the United States or 
Europe. It is, therefore, possible that CDI plays an important 
role in diarrhoeal illness in sub-Saharan Africa, yet there are 
few published data on the subject. Published infection rates 
vary greatly, with some authors describing 0% toxigenic C. 
difficile detection in Kenya and Zambia, while the highest 
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published rate is from Nigeria at 43%.25-27 The nature of  the 
relationship between HIV and CDI in sub-Saharan Africa 
remains poorly understood.
The aims of  this review are to describe current published 
literature regarding CDI in adults in sub-Saharan Africa, and 
to highlight areas warranting further research.
Methods 
In order to identify English-language publications since 
1995 assessing CDI in adults in sub-Saharan Africa, 
online databases (PubMed, Medline, Google Scholar, and 
SCOPUS) were searched, using combinations of  keywords 
“C. difficile”, “Africa”, and “HIV”. All relevant papers, in 
English, from 1995 onwards were included in the review, 
and their bibliographies were reviewed for relevant papers. 
Papers that looked for C. difficile in children were excluded. 
Papers looking at adults and children were only included if  
it was possible to distinguish between the two populations. 
In total ten relevant studies were found. Data were extracted 
from relevant papers using a standardised pro forma.
Results
Ten studies looked for toxigenic C. difficile carriage in sub-
Saharan Africa. Of  these, eight described toxigenic C. 
difficile carriage. Two studies from Kenya (1998) and Zambia 
(2000)6 did not find carriage of  toxigenic C. difficile.25,26 
There was considerable variation in laboratory methodology 
used to identify C. difficile and in the populations studied. 
Furthermore, there was wide variation in the methodology 
used to assess the association of  CDI with recent antibiotic 
usage, HIV, diarrhoea, and degree of  immunosuppression. 
Table 1 summarises current published studies of  CDI in 
adult populations in different countries in sub-Saharan 
Africa.
Discussion
The majority of  published studies, and all studies after the 
year 2000, describe carriage of  toxigenic C. difficile in adult 
populations in sub-Saharan Africa. In three studies, which 
assessed recent antibiotic usage, there was a significant 
association between antibiotic usage and CDI; however, 
no studies were designed to implicate individual antibiotics, 
nor to describe the nature of  antibiotic usage.29,30,34 These 
findings are consistent with the well-described risk factor 
of  antibiotic usage in high-resourced healthcare systems. 
In three of  four studies that assessed association with HIV 
status, no association was found. The only study claiming 
an association between HIV status and CDI in adults was 
from Nigeria. However, it compared toxigenic C. difficile 
carriage in an entirely HIV-positive sample from an urban 
teaching hospital, with a control population from a different 
geographical region, wherein HIV status was presumed to 
be negative if  unknown.27 A study of  adults and children in 
Tanzania found a significant difference in toxigenic C. difficile 
carriage between HIV-positive and HIV-negative individuals. 
It was not possible, however, to distinguish between adults 
and children in this analysis, and the number of  adults in 
the study was low.34 The lack of  association between CDI 
and HIV status in adults differed from observations in 
high-resource healthcare systems in the United States 
and Europe.18,20,21 The only study to assess the association 
between degree of  immunosuppression in HIV and CDI 
was from Malawi.31 This study showed no significant 
association between carriage of  toxigenic C. difficile and 
severe immunosuppression (CD4+ cell counts less than 50 
× 106/L), although numbers in this group were small. This 
warrants assessment in a larger study population.
A further area of  uncertainty is the role that C. difficile plays in 
diarrhoeal illness, as opposed to asymptomatic infection and 
incidental detection, in populations studied in sub-Saharan 
Africa. Table 1 shows that a wide variety of  laboratory 
methods have been used to detect C. difficile in the different 
studies, with different sensitivities and specificities. Methods 
that use cytotoxicity or immunogenic assays to detect C. difficile 
toxin reliably detect invasive CDI but sensitivity is variable 
and dependant on laboratory technique, while methods 
based solely on polymerase-chain-reaction (PCR) assays 
probably result in overdiagnosis.35-38 Only one study used the 
two-step diagnostic algorithms currently recommended in 
many countries, using assays for faecal C. difficile glutamate 
dehydrogenase (GDH) as a screening test for presence of  
infection, followed by confirmatory PCR for cytotoxin 
genes to diagnose invasive disease potential.35 The majority 
of  studies assessed C. difficile in patients with diarrhoea and 
did not compare these to non-diarrhoeal controls. However, 
the most robust study of  CDI in sub-Saharan Africa showed 
a clear association between detection of  toxigenic C. difficile 
and symptomatic diarrhoeal illness in South Africa.29 Another 
study of  adults and children in Tanzania detected toxigenic 
C. difficile in 9 of  141 subjects with diarrhoea, compared to 
none in the stools of  109 symptom-free controls.34 While 
asymptomatic carriage has been well documented and has 
been demonstrated to contribute to ongoing transmission of  
C. difficile in well-resourced healthcare systems, its significance 
in sub-Saharan Africa is uncharacterised.21,22,39,40
Only one study on CDI in South Africa described 
complications (other than diarrhoea) and prognosis.33 
There was an observed 66.7% mortality rate for patients 
with CDI and diarrhoea. However, there was no statistical 
difference in mortality between patients with or without C. 
difficile, nor in length of  stay and intensive care admission. 
Twelve percent of  patients with CDI required colectomy, a 
finding that was significantly associated with the presence of  
toxigenic C. difficile. The presence of  toxigenic C. difficile has 
been described in sub-Saharan Africa, but its disease burden 
and clinical significance, particularly in areas of  high HIV 
prevalence, remain poorly understood.
Conclusions
There are relatively few studies on CDI in sub-Saharan Africa, 
but toxigenic C. difficile has been detected in the majority of  
studies designed to look for it in the region, where it has 
been consistently associated with antibiotic usage. Further 
in-depth research is needed to define the epidemiology of  
CDI in sub-Saharan Africa in order to clarify the extent of  
colonisation within communities and among hospitalised 
populations, the extent to which CDI is associated with HIV 
and CD4 count, and its role in contributing to morbidity and 
mortality.
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Table 1:  Published studies on CDI in adults in sub-Saharan Africa, 1995 to present
Author Year Country Setting Controls
Diagnostic 
test for CDI
Sample size 
(adults)
CDI 
detection 
rate (adults)
Antibiotic 
association
HIV 
association
Mwachari25 1998 Kenya
HIV positive 
adult 
inpatients 
with chronic 
diarrhoea
n/a
Cytotoxicity 
assay 75 0% n/a n/a
Germani28 1998
Central 
African 
Republic
Adults 
presenting to 
hospital with 
diarrhoea 
HIV positive 
and negative 
non-
diarrhoeal 
adult 
inpatients
Cytotoxicity 
assay
430 0.7% n/a n/a
Zulu26 2000 Zambia
HIV positive 
adult 
inpatients
n/a
ELISA for 
toxin A 68 0% n/a n/a
Samie29 2008 South Africa
Adults and 
children in 
hospital and 
community 
with 
diarrhoea
HIV positive 
and negative 
non-
diarrhoeal 
adult in 
hospital and 
community 
PCR for 
cytotoxin 
genes
135 17.8% Yes No
Onwuema27 2011 Nigeria
Adults and 
children in 
hospital and 
community 
with 
diarrhoea
HIV negative 
(or unknown) 
adults in the 
community
EIA for toxin 
A and B
140
4.3% 
(community) 
to 43.5% 
(inpatient)
n/a Yes
Rajabally30 2013 South Africa
Adult 
inpatients 
with 
diarrhoea 
n/a EIA for toxin 
A
643 9.2% Yes No
Beadsworth31 2014 Malawi
Adult 
inpatients 
with 
diarrhoea
HIV positive 
and negative 
non-
diarrhoeal 
adult 
inpatients 
ELISA for 
toxin A and B
206 13.6% n/a No
Simango32 2014 Zimbabwe
Adults and 
children in 
community 
with 
diarrhoea
n/a
Culture and 
EIA for toxin 
A and B
159 6.9% n/a n/a
Kullin33 2015 South Africa
Adults in 
hospital and 
community 
with 
diarrhoea
n/a
PCR for 
cytotoxin 
genes
156 16% n/a n/a
Seugendo34 2015 Tanzania 
Adults and 
children 
inpatients 
with 
diarrhoea
Non-
diarrhoeal 
adults in 
community
Rapid test for 
GDH and 
PCR for 
cytotoxin 
genes
33 9.1% Yes Yes
CDI = Clostridium difficile infection; ELISA = Enzyme-linked immunosorbent assay; PCR= polymerase chain reaction; EIA = Enzyme immunoassay; n/a = not 
assessed; GDH = glutamate dehydrogenase (Clostridium difficile-specific)
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